Clinicians expectations about CFTR modulator therapy
The vast majority of clinicians declared to expect moderate to great improvements in lung disease (88%), nutritional status (90%), ability to perform activities of daily living (86%) and survival (76%) but none or slight effect on exocrine pancreatic sufficiency (71%), endocrine pancreatic function (71%) and liver disease (78%). More specifically, clinicians expect moderate to great improvement on the number of exacerbations (95%) and slowing down of annual decline in FEV1 (86%) but none or slight increase in FEV1 (63%) and little or no improvement of pulmonary imaging (59%).